title: Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion.
authors.forename: Marzia
authors.initials: M
authors.lastname: Defina
authors.forename: Michela
authors.initials: M
authors.lastname: Rondoni
authors.forename: Alessandro
authors.initials: A
authors.lastname: Gozzetti
authors.forename: Lara
authors.initials: L
authors.lastname: Aprile
authors.forename: Ida
authors.initials: I
authors.lastname: Chitarrelli
authors.forename: Alberto
authors.initials: A
authors.lastname: Fabbri
authors.forename: Francesco
authors.initials: F
authors.lastname: Lauria
authors.forename: Monica
authors.initials: M
authors.lastname: Bocchia
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002872:Chromosome Deletion; D002895:Chromosomes, Human, Pair 5 / Q000235:genetics*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D000970:Antineoplastic Agents; D013792:Thalidomide; D000077269:Lenalidomide